Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System

• Status: Not yet recruiting
• Trial end date: 2028-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to verify the safety and efficacy of Lepu® NeoVas™ Bioabsorbable Coronary Artery Rapamycin-eluting Stent System combined with different antiplatelet therapies in the treatment of coronary heart disease.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lepu Medical Technology (Beijing) Co., Ltd.

Criteria

Inclusion Criteria:

• Age 18 or above, male or non-pregnant female.

• Evidence of myocardial ischemia (e.g., stable angina, unstable angina, medium-low risk NSTEMI, STEMI with onset more than 1 week, old myocardial infarction or asymptomatic myocardial ischemia), and suitable for PCI surgery.

• The target lesion is in-situ coronary artery lesion, the total length of single lesion is no more than 40mm (the total length of stent is no more than 48mm), and the diameter of the target lesion is between 2.75mm and 3.75mm (visual measurement).

• The diameter stenosis of target lesion is ≥70% in visual (or ≥50% with clinical evidence of myocardial ischemia in that range), and the TIMI blood flow is greater than grade 1.

• The stent with diameter more than 3.0mm is allowed to overlap with another stent once, the overlapping methods could be edge to edge or at most 1mm overlap. The total number of stents per patient is no more than 4, with a maximum of 2 stents per vessel (the 2.75mm diameter stent is not allowed to overlap).

• Patient with indications for coronary artery bypass surgery.

• Aspirin and clopidogrel could be used continuously during the study.

• Patient who can understand the purpose of this trial, is willing to participate in the trial and to conduct clinical follow-up as required by the study protocol.

Exclusion Criteria:

• Acute ST-segment elevation myocardial infarction within 1 week.

• Left main coronary artery disease, branch vessel diameter≥2.0mm, three-vessel coronary artery disease and bridge vessel disease; visible thrombus in the target vessel.

• Severe distortion, severe calcification that cannot be successfully predilated, and other lesions that are not suitable for stent delivery and deployment.

• Intra-stent restenosis.

• Severe heart failure (NYHA≥III or left ventricular ejection fraction<35%).

• Severe renal insufficiency, eGFR<30ml/min/1.73m2 or serum creatinine>2.5mg/dL (221μmol/L).

• Patients with bleeding tendency, active gastrointestinal ulcer, history of cerebral hemorrhage or subarachnoid hemorrhage, history of stroke within half a year, fundus hemorrhage affecting vision, antiplatelet agents and anticoagulant treatment contraindications who cannot receive antithrombotic therapy.

• Patients requiring long-term oral anticoagulants during the study period.

• Patients who are pregnant, breastfeeding, or planning to become pregnant during the study period.

• Patients with malignancies, organ transplants, or drug addiction that can seriously affect study compliance.

• Patients with contraindications to aspirin, clopidogrel or ticagrelor.

• Known allergy to aspirin, clopidogrel, ticagrelor, heparin, contrast agent, polylactic acid polymer and rapamycin.

• Thrombosis occurred during previous clopidogrel treatment.

• Life expectancy is less than 36 months.

• Participated in clinical trials of other drugs or medical devices before enrollment and failed to meet the time limit of the primary end point.

• Patients who will have elective surgery within a year and need to discontinue aspirin, clopidogrel or ticagrelor.

• Subjects are deemed unsuitable for enrollment by investigators.